Wall Street equity research analysts covering InflaRx have established an optimistic average 12-month consensus price target, with projections clustering significantly higher than its current trading baseline. These target forecasts reflect analytical confidence in the commercial and clinical viability of the company's anti-inflammatory drug candidates. However, actual share price realization depends heavily on upcoming clinical trial milestones, regulatory milestones, and broader biotechnology sector market sentiment.